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A rapidly developing paradigm for modern health care is a proactive and individualized
response to patients’ symptoms, combining precision diagnosis and personalized treatment.
Precision medicine is becoming an overarching medical discipline that will require a better
understanding of biomarkers, phenotypes, endotypes, genotypes, regiotypes, and
theratypes of diseases. The 100-year-old personalized allergen-specific management of
allergic diseases has particularly contributed to early awareness in precision medicine.
Polyomics, big data, and systems biology have demonstrated a profound complexity and
dynamic variability in allergic disease between individuals, as well as between regions.
Escalating health care costs together with questionable efficacy of the current management
of allergic diseases facilitated the emergence of the endotype-driven approach. We
describe here a precision medicine approach that stratifies patients based on disease
mechanisms to optimize management of allergic diseases.
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Introduction and general concepts
Allergic diseases remain a worldwide problem, with almost one 
billion cases, causing significant morbidity and mortality and 
accounting for a considerable portion of health care expendi-
ture. The heterogeneous, dynamic combination of dysregulated 
immune response, chronic inflammation, tissue remodeling, and 
hyperresponsiveness in affected tissues defines the complexity 
of asthma, anaphylaxis, food allergy, allergic rhinitis, chronic rhi-
nosinusitis (CRS), and atopic dermatitis (AD).
At present, management guidelines for allergic diseases are 
based on evaluation of symptoms, target organ function, exacer-
bations, need for rescue medication, and limitation of quality of 
life, all the while reinforcing the importance of achieving disease 
control and reducing future risk (1). Nonetheless, the treatments 
available today merely offer long-term relief of symptoms and 
do not cure the disease, making it increasingly clear that new 
approaches for the management of allergic diseases are required. 
Accordingly, the current understanding of precision medicine has 
developed and is continuously improving (Table 1).
Disease phenotypes cluster together relevant visible prop-
erties such as age at onset, triggers, comorbidities, physiological 
traits, remodeling, inflammation type (eosinophilic and non- 
eosinophilic), and treatment response (2, 3). Asthma phenotypes 
defined based on the predominant inflammatory cell identified 
in induced sputum (eosinophilic, neutrophilic, mixed granulo-
cytic, and paucigranulocytic phenotypes) or in blood (eosino-
philic asthma) are currently being used for a stratified approach 
to severe asthma (4, 5). Phenotypes do not necessarily relate to or 
give insights into the underlying pathogenetic mechanism (2, 3). 
In addition, they frequently overlap and are subject to change over 
time (2, 6). Thus, defining disease endotypes based on key patho-
genetic mechanisms has become a rational development (2, 7–9). 
The development of precision medicine brought together its own 
taxonomy, summarized in Table 2.
The difficulty of the endotype-driven approach derives from 
the fact that even though endotypes linked to a single molecu-
lar mechanism can be defined, most endotypes share etiological 
and pathogenic pathways with nonlinear dynamic interactions 
that may or may not be present in all patients, or in each patient 
at all time points (Figure 1). Thus, the concept of dynamic com-
plex endotypes (e.g., the complex type 2 endotype), which consist 
of several subendotypes longitudinally, exists for allergic diseas-
es (10–12). A complex type 2 endotype involves Th2 cells, type 2 
innate lymphoid cells (ILC2s), type 2 subsets of B cells, type 2 sub-
set of NKT cells, eosinophils, mast cells, basophils, and their cyto-
kines (e.g., IL-4, IL-5, IL-13); IgE-isotype antibodies; surface mole-
cules such as CRTH2; and soluble mediators such as histamine. To 
confirm the validity of an endotype, longitudinal follow-up studies 
of clinical and molecular profiles need to be performed.
Biological markers (biomarkers) represent measurable indica-
tors linking an endotype with a phenotype (10, 13). At present, bio-
markers have been advanced that predict response to treatment in 
the endotype-driven approach in asthma, CRS, and AD. Regret-
tably, current biomarkers are not precise in selecting the specific 
endotype that will respond to a targeted treatment. A good exam-
ple is the observation that blood eosinophilia predicts therapeutic 
response to all currently available or future targeted interventions 
in severe asthma (i.e., anti–IL-5, anti–IL-4/IL-13, and anti-IgE tar-
geted treatment, CRTH2 antagonists) (13, 14).
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in which microRNAs (miRNAs) play a 
central role (Table 3). High-throughput 
profiling studies of well-characterized 
patients, including analyses of gene 
expression (e.g., microarrays and RNA 
sequencing transcriptomics), can help 
to identify combined signatures for type 
2 and non–type 2 endotypes. They are 
enriching the available data for the iden-
tification of new potential targets. As 
critical components in the regulation of 
tissue homeostasis, miRNAs represent 
a very attractive field of precision med-
icine research in asthma and allergic diseases, as they have been 
linked to many biological mechanisms underlying Th2 cell and 
macrophage polarization, regulation of ILC2 biology, steroid- 
resistant asthma phenotype, airway smooth muscle dysfunction, 
and impaired antiviral innate immunity (Table 3 and refs. 15–25). 
Thus, miRNAs represent a modifiable downstream target that 
will expand the precision medicine approach beyond the type 2/
non–type 2 paradigm.
In one notable example of this approach, the use of gene 
expression microarrays on bronchial epithelial cells obtained 
from patients with asthma led to the identification of periostin, 
an IL-13–responsive biomarker (26–30). However, expression sig-
natures are not highly specific for type 2 asthma: a recent study 
showed type 2 airway gene expression in a subset of patients with 
chronic obstructive pulmonary disease (COPD) (31).
The endotype-driven approach offers a way to better diag-
nose, monitor, and stratify patients (Figure 2). Biomarkers and 
combinations of biomarkers help tailor the management of aller-
gic diseases. Presently, the most salient obstacles to ubiquitous 
biomarker usage are its feasibility and the cost of measuring sam-
ples. Work is under way to create rapid point-of-care tests that are 
both user-friendly and low-cost. The advent of these new meth-
ods combined with insights into biomarker combination strategies 
will likely yield robust information that will improve diagnosis and 
management of allergic diseases.
Physiopathology of allergic diseases and 
endotypes
MicroRNA- and gene signature–based endotypes. There is exten-
sive posttranscriptional gene dysregulation in allergic diseases, 
Table 1. Comparisons between the traditional current approach and the precision 
medicine/stratified approach
Traditional approach Precision medicine/stratified approach
Methodology Evaluation of visible  
properties
Classify by risk Big data Surveillance for  
preclinical disease
Intervention One size fits all Tailored Unbiased Early intervention
Result Mixed results: 
Responders 
No effect 
Adverse events
Focus on responders  
for existing treatments
Discovery of  
new targets
Targeted prevention
 
Table 2. Nomenclature and key terms for the precision medicine/stratified approach
Term Definition
Phenotype Cluster of visible properties, attempting to individualize disease expression in groups of patients. A comprehensive set of visible properties is 
usually used and includes: clinical parameters (age, sex, race, disease onset, triggers, symptoms, etc.); physiological properties (upper and lower 
airway patency and hyperreactivity, ventilation pattern, olfaction, skin dryness, etc.); morphological features (airway smooth muscle hypertrophy, 
shedding epithelium, mucus production, nasal polyps, etc.); imaging (bronchial thickness, sinus CT); clinically relevant outcomes (exacerbations, 
lung function decline, recurrence of nasal polyps, etc.); inflammatory parameters (eosinophilic or neutrophilic inflammation); and treatment 
response (responder/nonresponder, corticosteroid sensitive or resistant).
Endotype Compilation of disease mechanisms explaining disease expression in groups of patients. The most common endotypes for allergic diseases are 
type 2 and non–type 2; however, recent data have emerged in support of inflammasome subtype, barrier subtype, type 17 subtype, and mixed 
types such as type 2/type 1 and type 2/type 17. 
Biomarker Measurable indicator linking disease endotype with the phenotype.
Theratype Prediction of treatment response based on the disease endotype.
Regiotype Regional difference between endotypes due to different allergens and other environmental influences. It is a new concept introduced in this paper.
Inflammasome endotype Subtype of non–type 2 immune response driven by overactivation of IL-1β and TNF-α/NF-κB pathway. It is usually non–steroid-responsive, and it 
can be accompanied by infections.
Barrier endotype Displays severe alterations of epithelial barrier function as driver of either disease sensitization or severe forms of disease. It is relevant to both 
type 2 and non–type 2 immune response.
Corticosteroid-responsive theratype Theratype that is decisive in corticosteroid treatment response in lung function, bronchodilator response, airway responsiveness, symptoms, need 
for oral steroids, and frequency of emergency department visits and hospitalizations.
Stratified medicine The endotype/biomarker-driven approach that classifies individuals into subpopulations that differ in their susceptibility to a particular disease or 
response to a particular treatment.
Stratification biomarkers Biomarkers serving to stage diseases based on prognosis or underlying biological mechanism, thus enabling the concept of enrichment.
Enrichment Selection of a patient population in which a successful intervention effect is more likely than in an unselected population.
Prognostic enrichment The selection of a patient population that is more likely to have a disease-related event, such as exacerbations, organ function decline, or death.
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North America and Eastern Europe, and olive and cypress in the 
Mediterranean, Middle East, southern regions of North Ameri-
ca, and Japan (38–40). A good example of heterogeneous disease 
appearance is in CRSwNP: in Chinese populations, polyps appear 
with a tendency toward neutrophil predominance, whereas polyps 
in Western populations are mostly eosinophilic (41–43).
Biomarkers are part of the regiotype concept that we are 
proposing. For example, serum periostin did not discriminate 
between asthmatics and nonasthmatics in a Chinese population, 
while in Japan and in white populations it is considered a good 
biomarker for type 2 asthma. Serum periostin levels were higher 
in the Chinese than in the Caucasian nonasthma group, and were 
also sex-dependent in the Chinese participants. This suggests that 
ethnicity should be considered in the interpretation of periostin 
levels in asthma patients, and sex is an additional consideration 
in Chinese patients (44). In addition, filaggrin mutations seem to 
play a less pathogenic role in patients of African origin than in indi-
viduals of European or Asian ancestry (45). In inner-city African 
American children, CXCL1, IL-5, IL-8, and IL-17A were positively 
associated with difficult-to-control asthma, while IL-4 and IL-13 
were positively associated with easy-to-control asthma (46).
Complex molecular pathobiology defines new 
endotypes and subendotypes
At present, two main subtypes of immune responses driving the aller-
gic disease endotypes have been defined: type 2–high and type 2–low 
(refs. 10, 11, 26, 47, and Figure 2). Several biomarkers were linked to 
the type 2–high endotype: total and specific serum IgE, serum peri-
ostin and dipeptidyl peptidase 4 (DPP4), blood eosinophils, and, for 
asthma, sputum eosinophils and exhaled nitric oxide. Most of the 
new biologic drugs target the type 2–high pathway: IgE, IL-5, IL-4/
IL-13, chemoattractant receptor–homologous molecule expressed 
on Th2 cells (CRTH2), thymic stromal lymphopoietin (TSLP).
Mechanisms of the type 2–high endotype. Eosinophils have been 
associated with asthma, CRSwNP, and AD in many studies. Anti–
Recently reported gene expression profiles support the con-
cept of complex endotypes. Specific gene expression profiles from 
induced sputum, nasal, and endobronchial brushings show severe, 
adult-onset asthma gene signatures associated both with eosin-
ophilic airway inflammation and mast cells and with type 3 ILCs 
(ILC3s), while childhood-onset asthma has signatures associated 
with induced lung injury (32). In patients with recurrent wheeze, 
orosomucoid 1–like protein 3 (ORMDL3) gene expression shows a 
linear correlation with the stimulator of interferon gene (STING), 
which controls TLR-independent cytosolic responses to viruses. 
STING promotes the transcriptional activity of ORMDL3 through 
the TANK-binding kinase 1–interferon regulatory factor 3–signal 
transducer and activator of transcription 6 (TBK1-IRF3-STAT6) 
complex (33). In CRS with nasal polyps (CRSwNP), polyp tissue 
gene expression analyzed by hierarchical clustering and principal 
component analysis showed the presence of a complex endotype 
for both eosinophilic and non-eosinophilic phenotypes. Type 
2 cytokines (IL-4, IL-5, CSF2) and cell cycle regulators (cyclin- 
dependent kinase inhibitor 1A and cyclin D1) were identified in 
association with tissue eosinophilia, while mainly interferons and 
acute inflammatory cytokines (IL-1 and IL-6) were demonstrated 
as upstream regulators in the non-eosinophilic phenotype (34).
NSAID-exacerbated allergic disease. NSAID-exacerbated 
respiratory disease (N-ERD) is a chronic eosinophilic, inflamma-
tory disorder occurring in patients with asthma and/or CRSwNP 
(35). It affects 1 in 10 patients with asthma and CRSwNP. Newly 
described subphenotypes and emerging subendotypes of N-ERD 
are potentially relevant to the development of new treatments, 
such as biologics. Novel mechanisms that can be subendotypes 
are continually being identified (36, 37).
Regiotypes: a new concept in precision medicine. The triggers of 
allergy and disease appearance vary widely between regions of 
the world. The predominant type of allergens is determined by a 
region’s source of allergens — for example, a high prevalence of 
allergy to birch and birch pollen in Nordic countries, ragweed in 
Figure 1. Factors influencing disease endotypes and precision medicine. (A) A multitude of factors can induce or suppress certain genes or pathways and 
may play a role in the development of certain phenotypes and endotypes as well as control of asthma. (B) Methodologies addressing the dynamic and com-
plex interaction between risk factors, disease phenotype and endotypes, and expression modulators in allergic diseases in the context of precision medicine.
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These data define an innate antiinflammatory property of airway 
mucins by which their glycan composition can control lung eosino-
philia through engagement of Siglec-F. Evaluation of turbinate tis-
sue sections from patients with CRS revealed a marked increase in 
the level of staining of both Siglec-8 and Siglec-9 ligands, suggest-
ing that inflammatory cells or mediators involved in the disease 
activate the submucosal gland cells to increase ligand expression 
(51). In type 2 nasal polyps, MUC5AC, MUC5B, and IL-4 receptor-α 
are overexpressed, supporting the role of IL-4 and IL-13 in upreg-
ulating mucin expression (42). In the future, the endotype-driven 
approach should be expanded beyond the type 2/non–type 2 para-
digm, and interventions should target specific molecular pathways 
such as IL-5–, IL-4/IL-13–, or IgE-driven inflammation as subendo-
types of the complex type 2 endotype.
Steroid-unresponsive subtypes. Over time, chronic inflamed 
airways can lose tolerance to immunogenic entities that are 
released following frequent eosinophil degranulation. A recent 
study reported a “polyclonal” autoimmune event in the airways of 
prednisone-dependent asthmatic patients with increased eosin-
ophil activity, recurrent pulmonary infections, or both, based on 
IL-5 interventions have been shown to have benefit in all these dis-
eases, suggesting that eosinophils, which are activated by IL-5, play 
a pathophysiological role. Mast cells and basophils are also present. 
Anti-IgE antibody interventions have shown efficacy in asthma 
and some efficacy in CRS, suggesting that mast cells and/or baso-
phils are involved as well. Eosinophils, mast cells, and basophils 
express sialoglycan-binding proteins (Siglecs) such as Siglec-8 and 
Siglec-9, which inhibit cell function and survival. Targeting Siglec-8 
or Siglec-9 with antibodies causes eosinophil and neutrophil death, 
especially in cytokine-primed cells. Siglec-8 targeting in mast cells 
does not induce cell death, but inhibits the activation of high-affin-
ity IgE receptors (FcεRI), triggering the release of mediators such 
as histamine and prostaglandin D2. Siglec-9 has also been shown to 
bind broadly to many different TLR agonists (48, 49). In the lung, 
mucin 5B (MUC5B) and MUC4 are carriers of sialylated glycan 
ligands for Siglec-F, and MUC1 is the ligand for Siglec-9 (50). Puri-
fied mucin preparations carrying sialylated and sulfated glycans 
have been shown to bind to mouse eosinophils and induce their 
death. Mice deficient in MUC5b displayed exaggerated eosinophil-
ic inflammation in response to intratracheal instillation of IL-13. 
Figure 2. The dynamic and complex interaction between risk factors, disease phenotypes and endotypes, and expression modulators in allergic diseas-
es in the context of precision medicine. In type 2 asthma, four main pathways can be targeted: the IgE pathway (omalizumab), the IL-5 pathway (mepo-
lizumab, reslizumab, benralizumab), the IL-4/IL-13 pathway (dupilumab, tralokinumab, lebrikizumab), and the CRTH2 receptor (fevipiprant and timapip-
rant). In non–type 2 asthma, three main pathways can be targeted: the inflammasome pathway (anti–TNF-α  interventions such as etanercept, infliximab, 
and adalimumab; anti–IL-1β interventions such as anakinra; anti–IL-6 targeting with tocilizumab or atlizumab; negative feedback with IL-37; or CD80-CD28 
blockade with abatacept), the IL-17 pathway (brodalumab), or the anti–IL-33 pathway, with CXCR2 and HMGB1/RAGE blockade as additional approaches. 
For the mixed complex endotypes, a combination of anti–type 2 interventions with antiinflammatory macrolides or anti-CXCR2 can be indicated. As an 
alternative, PI3Kδ/JAK/MyD88 inhibitors might block the upstream effects of type 1, type 2, and type 17 cytokines.
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ed by peptidase allergens (58). These mechanisms are accompa-
nied by protease-driven inflammatory events with intracellular 
generation of reactive signaling molecules and TLR4 activation. 
An analogous mechanism operates in skin, wherein house dust 
mite (HDM) protease allergens cause the epidermis to become 
leaky, then impede its restitution, while at the same time promot-
ing cytokine and chemokine production (59). Downregulation 
of phospholipase C-δ1 (PLC-δ1), which is normally abundantly 
expressed in the epidermis, impairs the barrier functions of the 
stratum corneum and the localization of TJ proteins (60). Phys-
iological levels of the cytokine oncostatin M impair barrier func-
tion in differentiated airway epithelium. Oncostatin M levels are 
increased in nasal polyps of CRS patients, in bronchoalveolar 
lavage fluid after segmental allergen challenge in allergic asth-
matic patients, and in sputum (61).
Immunometabolic changes associated with type 2 endotypes. 
Changes in metabolic functions of various cells have an import-
ant impact in asthma development in models. Models of abnormal 
NADPH oxidase 2 (Nox2) function suffer from hyperinflammato-
ry responses in lung as well as bacterial and fungal infection. Nox2 
deficiency (Nox2-null mice) results in exaggerated experimental 
evidence of sputum anti–eosinophil peroxidase and anti-nucle-
ar antibodies of the IgG subtype. In addition to displaying a type 
2 microenvironment, extensive profiling of sputum cytokines 
(including B cell–activating factor and B cell–attracting chemo-
kine 1) indicated the formation of ectopic lymphoid structures. 
Immunoprecipitated sputum immunoglobulins from patients with 
autoantibodies triggered eosinophil degranulation, with release of 
extensive histone-rich extracellular traps, an event unsuppressed 
by dexamethasone and possibly contributing to the patients’ ste-
roid-unresponsiveness (52).
Impairment of epithelial barrier: the leaky barrier endotype. 
Impaired tight junction (TJ) structures are observed in patients 
with asthma, AD, and CRS. Protease-containing allergens, envi-
ronmental pollutants, viruses, and type 2 cytokines enhance para-
cellular transport through disruption of epithelial barrier function 
(53, 54). The ability of protease allergens to cleave TJs directly 
and to affect their function via cytokine expression provides a 
powerful mechanism to compromise epithelial defense: IL-4 
and IL-13, released by Th2 cells and ILC2s, open the TJ barrier to 
cause a chronic epithelial barrier leakiness (55–57). Lung-specific 
claudin-18 is downregulated by IL-13, whose release is augment-
Table 3. miRNAs as biomarkers and as potential therapeutic targets
miRNA Biomarker value Therapeutic target Reference
miRNA profile of eosinophils Differs between asthmatics’ and healthy subjects’ eosinophils; classifies asthmatics  
into two clusters distinguished by number of eosinophils and serum periostin.  
Related to asthma severity
15
Epithelial and sputum miR-221-3p Related to airway eosinophilic inflammation Decreased epithelial miR-221-3p  
may protect against airway 
eosinophilic inflammation by 
upregulating antiinflammatory 
chemokine CXCL17
16
miR-708, miR-140-3p Distinct effects on inflammation-associated gene expression and biological function  
of ASM cells
17
miR-323-3p Controls production of IL-22 in IL-22/IL-17–producing T cells via negative feedback and 
thus may impact T cell responses
18
Circulating miRNA (miR-296-5p, 
-548b-5p, -138-5p, -16-5p, -1227-3p, 
-30d-5p, -203a-3p, -128-3p)
Significantly associated with AHR, with the strongest association for miR-296-5p 19
miR-16-5 Acts as a network hub involving multiple miRNAs interacting with genes in the FoxO  
and Hippo signaling pathways
19
miR-16-5, miR-30d-5p Effects on cell growth and diameter 19
miR-142-3p Regulates the balance between proliferation and differentiation of ASM cells in asthma 
via controlling WNT signaling 
May be a target to prevent ASM 
hyperproliferation in asthma
20
miR-9 Regulates glucocorticoid receptor signaling and AHR resistant to steroids Novel approach to treating  
steroid-resistant asthma
21, 22
miR-21 Drives severe, steroid-insensitive experimental asthma by amplifying PI3K-mediated 
suppression of histone deacetylase 2
Novel approach to treating  
steroid-resistant asthma
21, 22
Translational (polyribosome-bound) 
mRNA 
Key in the asthmatic epithelium (IL-1A and leukotriene B genes or α6 and α2 integrin 
alternatively spliced isoforms); transfection of this hub into bronchial epithelial cells  
from healthy donors mimicked asthma characteristics
23
miR-125b Upregulated in eosinophilic CRSwNP in both sinonasal and bronchial epithelial cells; 
suppressing 4E-binding protein 1 protein expression in airway epithelial cells may 
enhance type I interferon expression and tissue eosinophilia
24
miR-151 Involved in AD pathogenesis via regulation of IL-12 receptor B2 25
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asthma, which is caused by enhanced Th2 effector function in a 
T cell–intrinsic manner (62).
Variations in ILC2s underlie allergic subtypes. ILC2s play a role 
in both early- and late-onset type 2 endotypes (63–66). They also 
play a role in viral-induced airway hyperresponsiveness (AHR). 
ILC2s are induced by IL-33, which is implicated in the pathophys-
iology of asthma and allergic diseases (67). Influenza A virus can 
rapidly release IL-33 from alveolar macrophages and NKT cells, 
activating ILC2s and causing subsequent production of the type 
2 cytokines IL-13 and IL-5 (68). However, through amphiregulin, 
ILC2s also promote repair of wounded lung tissue after viral infec-
tion (69). ILC2s were shown to produce VEGFA, which drives AHR 
and facilitates autocrine regulation of IL-13 (70). Further, ILC2s 
support neuro-immune crosstalk: murine ILC2s express NMUR1, 
the receptor for the neuropeptide NMU, and signaling by NMU 
through this receptor amplifies ILC2-mediated immune respons-
es (71). Sex hormones also play a role in controlling ILC2 num-
bers. Female asthma patients have higher levels of ILC2s in their 
peripheral blood than male patients. Female mice also have more 
lung ILC2s than males, an apparent result of testosterone metabo-
lite–mediated inhibition of ILC2 numbers and activation (72, 73). 
ILC3s producing IL-17A might be important drivers in non–type 2 
asthma, as IL-17A and Th17 cells play a role in neutrophilic inflam-
mation, and glucocorticoid resistance has been associated with 
Th17-driven inflammation (74). HDM-induced airway inflamma-
tion, remodeling, and Th2/Th17-type cell accumulation involve 
STAT3 activation that can be prevented by specific inhibition of 
STAT3 (75). They are also involved in maintenance of mucosal 
homeostasis: human CD40L+ ILC3s provide innate B cell help and 
are involved in an innate immunoregulatory mechanism through 
induction of regulatory B cell differentiation (ref. 76 and Figure 3).
Additional subtypes involving dysregulation of cytokines. TSLP, 
IL-25, and IL-33 are implicated in the dysregulation of Th2 
immune responses in severe allergic asthma (77, 78). TSLP, a cyto-
kine secreted by epithelial and innate immune cells, stimulates 
type 2 cell responses. Dual stimulation of Th2 cells by TSLP and 
IL-4 produces higher amounts of IL-5 and IL-13 and other proin-
flammatory cytokines compared with stimulation with IL-4 alone. 
Children with asthma showed enhancement of TSLP-driven T cell 
responses in peripheral blood. These data support sequential cyto-
kine activation for pathogenic Th2 cell differentiation and provide 
a mechanistic basis for the therapeutic targeting of TSLP signaling 
in human allergic diseases (79). Aryl hydrocarbon receptor (AhR) 
activation aggravates allergic inflammation, and AhR activation 
by diesel exhaust particles mediates upregulation of IL-33, IL-25, 
and TSLP with Th2 activation, potentially linking environmental 
pollution and allergic severe asthma (80).
IL-37b, a member of the IL-1 regulatory cytokine family, can 
suppress innate immunity and inflammatory activity. IL-37–medi-
ated regulation of intracellular inflammation mechanisms links 
bacterial infection with the activation of human eosinophils. In 
a coculture of human eosinophils and bronchial epithelial cells, 
IL-37b showed remarkable suppression of TNF-α, IL-1β, IL-6, 
CCL2, and CXCL8 production that was evoked by stimulation 
with the bacterial TLR2 ligand peptidoglycan. In contrast, IL-37b 
blocked the activation of intracellular NF-κB, the PI3K/Akt path-
way, and ERKs 1 and 2 and suppressed gene transcription of aller-
gic inflammation–related PYCARD, S100A9, and CAMP (81).
Bitter taste receptors in allergy and precision medicine. Follow-
ing chronic inflammation in asthma, airway structural changes 
occur, including subepithelial fibrosis, increased airway smooth 
muscle (ASM) mass, gland enlargement, neovascularization, and 
epithelial alterations. Increased ASM mass is a hallmark feature of 
remodeling in asthma. Bitter taste receptors (T2Rs) are expressed 
on human ASM cells. Six subtypes (T2R10, 14, 31, 5, 4, and 19) 
were found at levels greater than β2-adrenergic receptor (β2AR) 
(82). Unlike β2AR-mediated bronchodilation, T2R function is not 
impaired in asthma and shows little tachyphylaxis. When stimu-
lated by the bacterial acyl-homoserine lactones, T2Rs on ASM 
may act to open airways and, together with T2Rs of cilia, maintain 
patency and promote clearance of pathogenic bacteria and debris 
in the lung during infection. T2R agonists (e.g., chloroquine and 
quinine) promote ASM relaxation and bronchodilation and inhib-
it mitogen-induced ASM growth by modulating mitochondrial 
structure and function, resulting in ASM cell death. The mito-
chondrial protein BCL2/Bnip3 plays a central role in T2R agonist–
induced autophagy (83). T2Rs have recently been identified as 
important players in sinonasal innate immunity and contribute to 
CRS. T2R38, T2R4, and T2R16 are ubiquitously expressed in the 
ciliated cells of the human sinonasal epithelium. The T2R isoform 
T2R38 (family 2 isoform 38) regulates sinonasal defense against 
Gram-negative organisms through detection of quorum-sens-
ing molecules secreted by pathogens (84). This activation trig-
gers the production of nitric oxide (NO), a potent antimicrobial 
defense molecule, in a calcium-dependent manner, which results 
in increased ciliary beat frequency and acceleration of sinonasal 
mucociliary clearance. NO also diffuses into the mucus and direct-
ly targets bacteria and viruses (85). Polymorphisms in T2R38 that 
Figure 3. The role of innate lymphoid cells in allergic 
diseases. Type 1, 2, and 3 ILCs play different roles in dif-
ferent endotypes of asthma. The findings mostly come 
from mouse models and detection of cells in body fluids.
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confer decreased receptor functionality lead to an increased sus-
ceptibility to Gram-negative infection and can predict surgical 
outcomes of patients with CRS without nasal polyps and biofilm 
formation (86, 87). T2R38’s ability to modulate the antimicrobial 
NO pathway makes it an attractive therapeutic target to promote 
endogenous immune responses in patients with upper respira-
tory infections. However, patients with homozygous AVI poly-
morphisms (i.e., individuals expressing AVI/AVI), which render 
T2R38 nonfunctional, would be predicted to be less responsive to 
the treatments with T2R38 agonists. It therefore remains import-
ant to identify other T2Rs that activate similar mechanisms.
T2R4 and T2R16 signal through the same NO pathway, inde-
pendent of T2R38, and thus may be additional targets for novel 
therapeutic interventions. Keratinocytes express T2R1 and T2R38, 
which play a role in keratinocyte differentiation by inducing ker-
atin 10, involucrin, and transglutaminase expression, as proven 
by stimulation of keratinocytes with their agonist, amarogentin 
(88). Amarogentin inhibited substance P–induced production of 
newly synthesized TNF-α in mast cells, but their degranulation 
and release of stored histamine were not affected. In keratino-
cytes, amarogentin reduced histamine- and TNF-α–induced IL-8 
and MMP-1 expression to an extent similar to that achieved by 
the histamine H1 receptor antagonist azelastine (89). In a proof-
of-concept study, Gentiana lutea extract (containing amarogentin) 
significantly increased the lipid content of the treated skin areas. 
Enhancing lipid synthesis in human keratinocytes is essential for 
building an intact epidermal barrier, and therefore this therapeu-
tic approach might be used to improve skin disorders like AD that 
are characterized by an impaired epidermal barrier (90).
How T2Rs relate to precision medicine is an important ques-
tion. T2Rs are a novel target for asthma, CRS, and AD treatment 
independent of the inflammatory profile (type 2 or non–type 2) and 
could be the perfect example of a smart drug design starting from 
the endotype and theratype and extending through the drug devel-
opment program. They are also related to disease outcomes (asth-
ma control, CRS severity) and display significant heterogeneity, 
which affects their function. For example, genetic variations were 
associated with lower asthma control and better bronchodilator 
response (91). T2R38 genetic polymorphism predisposes to infec-
tion in upper airways via decreased NO production from epithelial 
cells in response to bacterial products (84). Allele expression stud-
ies in patients with CRS show that T2R38 is not the only genetic 
determinant of disease severity. Several other loci, such as that of 
TAS2R14 and TAS2R49, show an allele frequency difference of 
more than 10% between CRS patients and controls (92). Human 
skin expressed T2Rs, and the relative amounts differ markedly 
among individuals based on sun exposure, sex, and age (93).
Endocannabinoids in the type 2 allergic response. Endogenous can-
nabinoids acting via cannabinoid 2 (CB2) receptors play important 
roles in both homeostatic and inflammatory processes in the lungs, 
including eosinophilic inflammation and the suppression of ILC2s 
by NK cells. CB2 activation controls NK cell activity and induces a 
predominant type 2 microenvironment and eosinophilia (94, 95).
Olfactory receptors and the gut-lung axis. ASM olfactory recep-
tors (ORs) do not bronchodilate, but rather modulate cytoskeletal 
remodeling and hyperplasia, two cardinal features of asthma (96). 
Short-chain fatty acids (SCFAs), the by-products of fermentation 
of polysaccharides by the gut microbiome, activate these receptors, 
thus supporting a nonimmune gut-lung axis that may affect asthma 
susceptibility (96). Given the link between obesity and asthma, this 
potential interaction requires further exploration. Agonists direct-
ed to ORs might mitigate increases in ASM in asthma. Alternative-
ly, dietary modification to promote microbial communities (and 
the appropriate substrates) to generate SCFAs as natural agonists 
for ORs might represent a nonpharmacological approach.
Corticosteroid responsiveness theratype. It was recently hypoth-
esized that treatment response in lung function, bronchodilator 
response, airway responsiveness, symptoms, need for oral steroids, 
and frequency of emergency department visits and hospitalizations 
are modulated by a single quantitative corticosteroid responsive-
ness endotype or, perhaps more accurately, a theratype. A composite 
corticosteroid responsiveness theratype was tested in four replica-
tion populations. This composite theratype measured the endophe-
notype with higher accuracy, higher stability across populations, 
and higher robustness to missing data than any clinical phenotype 
(97). Accordingly, several SNPs have been described that associ-
ate with response to common asthma controllers (98–103) or with 
response to treatment of asthma exacerbations (104, 105). There 
are also SNPs that predict one of the adverse effects of inhaled cor-
ticosteroids (ICS), which is adrenal suppression (106, 107).
In asthma clinical trials, surrogates such as blood or spu-
tum eosinophils and exhaled NO have been used. For example, 
blood or sputum eosinophil counts have been used to titrate 
inhaled corticosteroids, and this intervention yielded better 
results compared with guidelines-driven asthma management 
in decreasing exacerbation (108).
Fibrotic mechanisms contribute to asthmatic responses. Activin 
A induces lung fibroblast proliferation and differentiation into 
myofibroblasts, and stimulates the production of collagen (81). 
Follistatin is a protein that binds activin with high affinity and 
low reversibility and antagonizes the pleiotropic actions of activ-
in. Follistatin-like 3 (FSTL3), a glycoprotein secreted by bronchial 
epithelial cells that binds to and inhibits activin A, is diminished 
in children with asthma, especially when airway obstruction is 
present. Decreased FSTL3 expression in the asthmatic bronchial 
epithelium led to subepithelial fibrosis (109).
The microbiome in allergic endotyping. High microbial diversity 
in the environment has been associated with lower asthma risk, 
particularly in children living in farm environments and exposed 
to farm milk. This effect operates through alterations in the micro-
biome of airway mucosal surfaces (110). Extensive molecular 
analysis of host and commensal microbe interactions continues, 
and has thus far generated several major molecular findings rele-
vant to asthma pathogenesis that together open a new concept for 
disease endotyping related to microbiome (111).
Metabolites of microbes regulate immune responses in sev-
eral aspects. Decreased fatty acid desaturase activity is observed 
in patients with asthma, and experimental models in mice and 
human epithelial cells suggest that inhibition of desaturase activ-
ity leads to AHR and reduced antiviral defense (112). Bacterial 
production of histamine and other monoamines was recently 
revealed as a possible concept in the pathogenesis of several dis-
eases and should be further explored (113–115). Bacteria-derived 
SCFAs, such as butyric acid, propionic acid, and acetic acid, have 
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tion, and personalized therapy. Despite the higher cost and oper-
ational complexity of these technologies, they enable real-time 
analysis of dynamic cell-cell interactions together with the ability 
to stretch the cells, mimicking expansion and retraction, as well 
as the ability to study inhalation exposure under physiological 
breathing. These methods also provide a high-resolution kinet-
ic analysis of biological responses (e.g., time-course release of 
secreted factors in response to challenge) (121). The small airways 
disease asthma phenotype, which is not easily accessible through 
classic biopsies, is particularly amenable to the small airway-on-a-
chip technology. Bioelectronics has enabled development of bio-
sensors that can detect biological signals in a living microenviron-
ment using micro- or nanofabricated probes. Thus the formation 
and disruption of epithelium barrier function can be investigated 
noninvasively in real time (122). In a recent study using this tech-
nology, a significant increase in the number of mucin-producing 
cells and secretion of proinflammatory cytokines, as well as a 
decrease in ciliary beat frequency, was observed in IL-13–treated 
mucociliated airway epithelial cells. The same study showed the 
ability of tofacitinib to reverse the observed asthmatic phenotypes 
to normal levels by inhibiting Janus kinase signaling (123).
Conclusions
Precision endotyping that links pathobiological mechanisms with 
visible properties via specific biomarkers and can be translated 
into pathway-specific diagnostic tests opens a pathway to accurate 
disease classification and individualized targeted treatments. It is 
expected to change the diagnostic and therapeutic landscape of all 
medical disciplines. Endotype-driven treatment still faces multiple 
challenges before its implementation in daily practice in allergic 
diseases and asthma. Currently, most of the endotype research is 
conducted in severe forms of allergic diseases; however, endotypes 
should be considered as a disease entity on their own. Early endo-
typing of milder or at-risk patients might provide more insight into 
disease mechanisms. At the early stages of the disease, putative 
endotypes may be easier to differentiate, while as the disease pro-
gresses, other cell types and structures would be affected, making 
the distinction of each endotype more difficult. Sustainability of an 
endotype is one of the major questions. Although a stable endotype 
has been observed in the absence of disease exacerbation, changes 
in an endotype can be observed during exacerbations, in smokers, 
during development of COPD, or during a shift from asthma to 
asthma-COPD overlapping syndrome.
A huge amount of omics data has been developing during recent 
years that can only be rationally analyzed in depth with cooperation 
between biologists, data scientists, and health care professionals. 
Translational bioinformatics had been proposed and developed as 
a new field only recently. The emergence of deep learning and arti-
ficial intelligence has impacted numerous machine learning–based 
applications and much research. The reason for their success lies 
in two main advantages: they provide the ability to learn very com-
plex nonlinear relationships between features, and they allow one 
to leverage information from unlabeled data that do not belong to 
the problem being handled. The deep learning–based molecular 
disease classification can be used to guide decisions made on the 
diagnosis and treatment of allergic diseases, and therefore may 
have important applications in precision medicine.
also been shown to be active in many inflammatory diseases, in 
particular butyrate in asthma models. Particular gut commensals, 
such as Bifidobacterium longum, are known to show protection 
from inflammatory diseases. Recently, a molecular mechanism of 
action was ascribed to exopolysaccharide produced by the com-
mensal bacteria (116, 117).
Treatable traits and asthma management. A new taxonomic and 
management approach, termed treatable traits, has been proposed 
for airway diseases including severe asthma, and eosinophilia is 
included as a treatable trait, indicating potential response to inter-
vention with corticosteroids. Treatable traits can be assessed using 
asthma registries. Patients with severe asthma express more treat-
able traits than patients with nonsevere asthma associated with 
risk of future asthma exacerbation, demonstrating the clinical utili-
ty of assessing treatable traits. In Australasia, allergic sensitization, 
upper airway disease, airflow limitation, eosinophilic inflamma-
tion, and frequent exacerbations, as assessed using a severe asth-
ma registry, were common in severe asthma. Among the traits that 
most strongly predict exacerbation risk in asthma are proneness 
to exacerbations, depression, inhaler device polypharmacy, vocal 
cord dysfunction, and obstructive sleep apnea. The treatable traits 
concept develops in parallel to endotypes and phenotypes and will 
probably find a niche in personalized medicine (118).
Tissue responses and disease endotypes
Using microarray and PCR analyses of airway epithelial brush-
ings, Woodruff was the first to classify asthma based on high or 
low expression of IL-13–inducible genes (periostin, chloride chan-
nel regulator 1, and serpin peptidase inhibitor, clade B, member 
2). This classification was validated through analyses of cytokine 
expression in bronchial biopsies, reproducibility on repeated 
examination, and relation with clinical endpoints such as lung 
function and responsiveness to inhaled corticosteroids (26).
Inflammatory signatures of CRS vary around the world, with 
less eosinophilic and more neutrophilic inflammation found in 
Asia compared with Europe and North America. These differenc-
es are associated with a lower asthma comorbidity and risk of dis-
ease recurrence after surgery in the Asian population. Interesting-
ly, the percentage of type 2 signature disease in patients with CRS 
is dramatically increasing in several Asian countries over the last 
20 years (this phenomenon has been termed eosinophilic shift). 
As a hallmark of severe type 2 inflammation, eosinophils attacking 
Staphylococcus aureus at the epithelial barrier have been described 
recently; they can also be found in a subgroup of Asian patients 
with nasal polyps (119).
Expression profiling of skin biopsy specimens has established 
molecular features of the skin in patients with AD. The minimally 
invasive skin tape strip transcriptome analysis has been evaluated 
for its value to describe molecular disease endotypes. Skin tape 
expression profiles were deemed better at evaluating epidermal 
differentiation complex genes. Both immune- and epidermis- 
related genes distinguish patients with AD from healthy subjects. 
Fifty percent of AD patients exhibit a type 2–high endotype that is 
characterized by more severe disease (120).
The “lung- and small airway-on-a-chip” technologies will 
rapidly contribute to filling the current translational gap in lung 
research and advance drug development, biomarker identifica-
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between age groups is also interesting. The ALL Age Asthma 
Cohort (ALLIANCE) offers a unique, integrative, and interdisci-
plinary framework with a comprehensive molecular approach in 
a prospective and identical fashion across ages in order to identify 
biomarkers and predictors for distinct childhood wheeze and asth-
ma trajectories as well as their further course during adulthood 
(125). Taken together, the implementation of precision medicine 
in clinical practice should consider insight into high-risk groups 
indicated by public health studies, including those linked to age, 
sex, and ethnicity.
Finally, collaboration of health care providers with pharma-
ceutical and biotechnical companies, scientific organizations, and 
governmental regulatory agencies will play a crucial role in better 
control and even cure of allergic diseases within the framework set 
forth in this Review.
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It is becoming increasingly obvious that a revised taxonomy 
of allergic diseases based on precision medicine and endotype 
profiling is necessary to stimulate targeted research and identify 
biomarkers that can predict patient response to treatment. Type 2 
and non–type 2 allergic disease profiling should involve the inter-
connected concepts of phenotype-biomarker-endotype, but also 
expand toward new targets such as ASM, epithelial components, 
and epigenetic modifications. In the future, many new endotypes 
and theratypes particularly defined by treatment response will be 
introduced. It is important to emphasize here that there are many 
clinical studies ongoing, with biologicals that target single cyto-
kines in the pipeline. Combination therapies and dual-specific 
antibodies are also ahead.
The endotype-driven strategy should be modeled per race, 
per age group, and per sex, because disease endotypes are also 
modulated by unmodifiable factors, such as race/ethnicity, sex, 
and age. For example, neutrophilic inflammation is more fre-
quently encountered in women, teenagers, or the elderly, or in the 
Chinese population. 17q21 gene variants are the strongest known 
genetic determinants for childhood asthma; however, they do not 
substantially influence asthma risk in adulthood or susceptibil-
ity to detrimental effects of active smoking. This contrasts with 
the findings in children and suggests that this locus is associated 
with a childhood-specific asthma endotype (124). The transition 
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